Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carrie Swartz

Gynecology Albuquerque, NM Medical Doctor

NPI 1386653822 CMS profile 107704

5150 San Francisco Rd Ne, Albuquerque, NM 87109

Open in the dashboard

General payments

$84,481

170 records reported · program years 2019–2025

Research payments

$1,531

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,593,509 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Carrie Swartz of Albuquerque, NM is reported in the CMS Open Payments database as having received $84,481 across 170 general payments and $1,531 in research payments paid to them. Separately, studies naming them as principal investigator received $1,593,509 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $433 4
2024 General $1,556 9
2023 General $17,208 15
2022 General $2,070 10
2021 General $8,714 8
2020 General $9,670 23
2020 Research $1,281 1
2019 General $44,830 101
2019 Research $250 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Swartz
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Carrie Swartz were reported at $433. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Carrie Swartz Gynecology median Middle half National median
2019 $44,830 $199 $66–$472 $163
2020 $9,670 $114 $42–$287 $114
2021 $8,714 $141 $42–$430 $132
2022 $2,070 $173 $52–$532 $149
2023 $17,208 $170 $57–$501 $160
2024 $1,556 $157 $50–$424 $164
2025 $433 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $50,353 102 payments
  2. Acessa Health Inc. $19,984 12 payments
  3. Acessa Health Inc. $7,088 18 payments
  4. Astellas Pharma US Inc $5,758 10 payments
  5. Hologic, LLC $868 5 payments
  6. CooperSurgical, Inc. $103 6 payments
  7. TherapeuticsMD, Inc. $83 4 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $74 4 payments
  9. Organon LLC $48 3 payments
  10. Allergan Inc. $36 2 payments
  11. Other $86 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,665 42 payments
  2. Consulting Fee $25,838 17 payments
  3. Travel and Lodging $2,827 25 payments
  4. Food and Beverage $2,136 84 payments
  5. Education $15 2 payments
Products named General payments · program years 2019–2025
  1. Orilissa Endocrinology $40,402 77 payments
  2. ACESSA PROVU SYSTEM Surgical $15,194 12 payments
  3. Acessa $7,088 18 payments
  4. Veozah $5,736 9 payments
  5. ACESSA PROVU SYSTEM Surgical $5,600 2 payments
  6. ORIAHNN $4,957 9 payments
  7. ORILISSA Womens Health $4,950 13 payments
  8. CoolSeal Generator $111 1 payment
  9. LO LOESTRIN FE $67 4 payments
  10. Mirena $60 3 payments
  11. Other $559 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Gynesonics, Inc. $1,531 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

41

Median for Obstetrics & Gynecology: 65

Drug cost

$1,330

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

31.7%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol (Twice Weekly) Estradiol Brand 13 $1,102
Medroxyprogesterone Acetate Generic 11 $203
Misoprostol Generic 17 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$8,986

Medicare's payments for the services billed

Medicare patients

33

Average age 68

Services billed

100

33 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 45%
Heart failure 0%
Atrial fibrillation 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $81
$81 — —
ORILISSA
  • AbbVie, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record